Roam Robotics Launches Partnership with the San Francisco VA Health Care System

To study the impact of its robotic wearable on the Veteran population

Roam Robotics, the company leading the expansion of human mobility with wearable robotics, announced today that the San Francisco VA Health Care System (SFVAHCS), along with the Northern California Institute for Research and Education (NCIRE), has begun enrolling patients to study the impact of Ascend, a first-of-its-kind smart brace, on the Veteran population.

Ascend, from Roam Robotics, is a smart knee orthosis designed to provide relief from knee pain and intuitively support everyday mobility. A previous clinical study of knee osteoarthritis participants demonstrated an average of 46 percent pain reduction, and 67 percent exhibited functional improvement when using the device.  Ascend is the first wearable robotic device to show usefulness in everyday life for people suffering from knee joint pain who want to regain independence and live more active lifestyles.  Ascend is also registered with the FDA as a Class I medical device.

“I am excited to evaluate Roam Robotics’ Ascend powered knee-brace in Veterans with knee osteoarthritis who experience considerable knee pain when performing day-to-day activities,” said Dr. Alfred Kuo, Chief of Orthopedic Surgery at the San Francisco VA Health Care System “Veterans suffer from musculoskeletal conditions such as knee arthritis at higher rates than the general population.  We don’t have great treatment options for many of these patients, especially ones who have moderate disease. The Ascend brace has the potential to substantially improve pain, stability, and function.”

Ascend provides a non-opioid and non-surgical solution for pain relief and increased stability, while performing common movements like walking, kneeling, standing, sitting, and going up or down steps. “Roam’s technology has been proven previously to provide benefits to a wide variety of patients suffering from knee pain, weak quadriceps or instability,” said Sujit Dike, Vice President at Roam Robotics. “We are very excited about this partnership with the   San Francisco VA. It can further validate the potential impact of Roam’s technology in addressing an enormous and growing challenge for the Veteran population”.

“Roam is focused on a massively underserved market.  More than 20 percent of the global population is limited by their body’s mobility, and as medical advancements help people live longer that number is only going to increase,” said Tim Swift, Roam’s CEO and Founder.  “Our approach to wearable robotics works seamlessly with the human body to help people lead healthier, happier and more active lives, unhindered by physical limitations.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.